In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT01453140 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Dose Limiting Toxicities

Conditions

Graft Versus Host Disease

Interventions

DRUG: Cyclophosphamide and Sirolimus
DRUG: Low dose IL-2 with Cytoxan + Sirolimus
DRUG: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
DRUG: Cyclophosphamide and Sirolimus
DRUG: Low dose IL-2 with Cytoxan + Sirolimus
DRUG: Low dose IL-2, Vidaza, Cytoxan & Sirolimus

Sponsor

Hackensack Meridian Health